Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Avante Biocapital is a pan-European venture capital fund established to support clinical-stage biotech companies. Founded with the mission to leverage European scientific excellence, the firm aims to create global leaders in the biotech sector. The organization recognizes the unique challenges faced by European biotech firms, particularly undercapitalization and operational gaps, and seeks to address these issues through strategic investments.
Currently, Avante Biocapital operates with a team of six members, including key leadership roles such as the CEO and Managing Partners. The firm focuses exclusively on clinical-stage biotech companies across Europe, providing not only capital but also operational support to assist in scaling and exiting these companies. Their commitment to fostering growth in the European biotech landscape positions them as a significant player in the venture capital space.
Avante Biocapital invests in clinical-stage biotech companies across Europe, targeting various stages of development including pre-seed, seed, Series A, and growth equity. The firm’s investment strategy is designed to address the challenges faced by the European biotech sector, particularly undercapitalization and operational inefficiencies. By providing long-term capital and hands-on operational support, Avante Biocapital partners with promising biotech firms to guide their strategy and execution.
The organization emphasizes the importance of operational excellence in scaling biotech companies. Their approach includes identifying high-potential firms, collaborating closely with them, and assisting in navigating the complexities of the biotech landscape. This focus on operational support differentiates Avante Biocapital from other investors, making them a valuable partner for startups in the biotech and healthcare sectors.
Matthew Foy - CEO, Managing Partner. Matthew has extensive experience in the biotech sector, having led multiple successful investments and exits in clinical-stage companies.
Mette Kirstine Agger - Managing Partner. Mette brings a wealth of knowledge in operational excellence and has a strong background in supporting biotech startups.
Bastiano Sanna - Head of Executional Excellence and Partner. Bastiano specializes in operational strategy and has a proven track record in guiding biotech firms through growth phases.
James Burr - Head of Investor Relations and Partner. James focuses on building relationships with investors and ensuring effective communication between the firm and its stakeholders.
Beatris Packard - Chief of Staff to the CEO. Beatris plays a crucial role in supporting the CEO and managing internal operations within the firm.
To pitch Avante Biocapital, startups should send their proposals via email to info@avantebiocapital.com. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Response times may vary, so founders should be prepared for a potential wait.
What are Avante Biocapital's investment criteria?
Avante Biocapital focuses on clinical-stage biotech companies across Europe. They seek firms that demonstrate potential for growth and innovation in the biotech sector, particularly those addressing significant healthcare challenges.
How can startups apply or pitch to Avante Biocapital?
Startups can reach out to Avante Biocapital via email at info@avantebiocapital.com. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Avante Biocapital different from other venture capital firms?
Avante Biocapital distinguishes itself by providing not only capital but also operational support to its portfolio companies. Their hands-on approach helps startups navigate the complexities of the biotech industry, which is often characterized by unique challenges.
What is the geographic scope of Avante Biocapital's investments?
The firm invests exclusively in clinical-stage biotech companies located in Europe, focusing on leveraging the region's scientific expertise.
What is the typical check size for investments?
While specific check sizes are not disclosed, Avante Biocapital invests across various stages, including pre-seed, seed, Series A, and growth equity, indicating a flexible approach to funding.
What kind of post-investment involvement can startups expect?
Avante Biocapital provides hands-on operational support post-investment, assisting portfolio companies in scaling their operations and preparing for successful exits.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.